Menu
Enrolling by invitation NCT06215105

Complex Aneurysm Registry - Real-World Evidence Data Collection Intracranial Aneurysm Treatment Devices

Observational Aneurysm Cerebral

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Intracranial Aneurysm Devices.
Who it may be relevant to
Registry conditions: Aneurysm Cerebral. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of commercially available MicroVention devices used for the endovascular treatment of intracranial aneurysms (IA) at the direction of the treating physician.

Interventions

  • Device Intracranial Aneurysm Devices
    Intracranial Aneurysm occlusion

Primary outcome measures

  • RROC [Time frame: 1 year]
  • RROC [Time frame: 1 year]
  • RROC [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • Patient must have a single ruptured or unruptured IA for which endovascular treatment has been determined appropriate.
  • Patient's IA will be treated using a commercially available MicroVention implant device as the primary treatment device and the decision to use this device has been made by the treating physician outside the context of the CAR study and prior to enrollment.

Note: For the purposes of this protocol, ancillary/accessory devices such as balloon catheters and other access devices are not considered primary treatment devices.

  • Patient or patient 's legally authorized representative (LAR) has provided written informed consent prior to treatment or no later than 48 hours post procedure for emergent treatment of a ruptured aneurysm.
  • Patient must be considered by the treating physician to be available for and able to complete study follow-up visits.

Exclusion criteria

  • Target aneurysm has been previously treated via surgical or endovascular means.
  • Patient is enrolled in another device or drug study in which participation could confound study results.
  • Patient has a life expectancy of less than 1 year due to other illness or condition (in addition to an intracranial aneurysm).
  • Patient has been previously enrolled into this study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

United States · 5 centers
  • Memorial Healthcare System — Hollywood
  • Orlando Health — Orlando
  • University of Iowa — Iowa City
  • Abbott Northwestern Hospital — Minneapolis
  • Albany Medical Center — Albany

Identifiers

NCT: NCT06215105 · CL11025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗